Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Today's news release

<< Previous

Bullboard Posts

Next >>

Comment by Cool_Lawon Mar 05, 2021 12:30pm

125 Views

Post# 32728924

RE:RE:RE:Today's news release

Here is the link for those that have interest in the stock....they will collaborate with the Salzman Group.

Claritas (formerly Kalytera Therapeutics, Inc.) to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant COVID-19, Influenza, and Other Viral Infections | 2021-03-03 | Press Releases | Stockhouse

MinimumDamage wrote: Dude51 - (3/5/2021 11:05:44 AM)
RE:Today's news release
Hit the road loser. Still looking for that link, shiit for brains.

Kalytera Will Not Proceed with Acquisition of Salzman Group at This Time

Following termination of the BARDA Contract, on about September 28, 2020 Kalytera determined that it was no longer in the best interests of the Company to go forward with the acquisition of the Salzman Group. Instead, the Company will proceed to develop R-107 under the Company’s exclusive world-wide license for the development and commercialization of R-107 for the treatment of COVID-19 infection. (We can't use applications of Nitic Oxide for anything other than coronaviruses + Covid-19)
https://claritaspharma.com/kalytera-provides-corporate-update/

As for the GVHD program

Summary of Transaction Terms
As consideration for the Acquisition, Kalytera will provide a combination of cash, securities, and future contingent payments to Talent.

This means, since Kalytera got GVHD and didn't pay in full, we were in debt and held liable to produce results with anticipated milestones in order to enhance the value of the company. It translates to : We cannot start another hefty project (R-107), as we made agreements to fully focus our energy and time on this since it would create conflict for Talents private shareholdings. Since it wasn't disclosed, we must assume in the resulting termination and forfeiture of GVHD back to Talent Bio to pay off debts. Which would give us the legal right of starting another project (menstrual cramps, Pain treatment, R-107, etc).

https://kalytera.co/news/kalytera-completes-acquisition-of-talent-biotechs/